Commentary

Video

The Impact of the Ponatinib FDA Approval in Newly Diagnosed Ph+ ALL

Author(s):

Ibrahim Aldoss, MD, City of Hope Comprehensive Cancer Center,Elias Jabbour, MD, MD Anderson Cancer Center

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the impact of the FDA approval of ponatinib for the treatment of newly diagnosed patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Related Videos
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Francine Foss, MD
David C. Fisher, MD
Alex Herrera, MD
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
Bertram Yuh, MD, MISM, MSHCPM
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
Related Content
Jorge E. Cortes, MD, of Georgia Cancer Center
November 21st 2024

An Era of Firsts in CML: Asciminib Challenges SOC TKIs

Jaffer A. Ajani, MD, GI medical oncologist, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
November 14th 2024

FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
November 15th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

Ravi Salgia, MD, PhD, professor, chair, Department of Medical Oncology & Therapeutics Research, Arthur & Rosalie Kaplan Chair in Medical Oncology & Therapeutics Research, City of Hope
September 2nd 2024

Salgia Summarizes the Benefits of Tepotinib in MET Exon 14–Mutated NSCLC

FDA
November 14th 2024

FDA Approves Nilotinib Tablets Without Mealtime Restrictions for CML

Alex F. Herrera, MD
November 14th 2024

Data for Nivolumab Plus AVD Could Help Harmonize Treatment of Older and Younger Advanced-Stage Hodgkin Lymphoma